Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Zammit

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Sleep Medicine|July 25, 2017
Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active referenceJed Black, Giora Pillar, Jan Hedner, et al.
JAMA Network Open|December 28, 2019
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical TrialRussell Rosenberg, Patricia Murphy, Gary Zammit, et al.
CNS Drugs|July 21, 2023
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and ZolpidemTobias Di Marco, Thomas E Scammell, Michael Meinel, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 20, 2021
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsyRussell Rosenberg, Michael J Thorpy, Yves Dauvilliers, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|October 26, 2017
Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled StudyPatricia Murphy, Margaret Moline, David Mayleben, et al.
Sleep|June 26, 2020
Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2Mikko Kärppä, Jane Yardley, Kate Pinner, et al.
Behavioral Sleep Medicine|June 13, 2024
Integration of Sensor-Based and Self-Reported Metrics in a Sleep Diary: A Pilot ExplorationSarah Conklin, Jessica R Dietch, Golshan Kargosha, et al.
The Lancet. Neurology|January 22, 2022
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trialsEmmanuel Mignot, David Mayleben, Ingo Fietze, et al.
Journal of Clinical Pharmacology|April 24, 2015
Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjectsNaoto Uemura, Jacqueline McCrea, Hong Sun, et al.
Journal of Sleep Research|June 10, 2024
Hyperarousal features in the sleep architecture of individuals with and without insomniaTobias Di Marco, Thomas E Scammell, Kolia Sadeghi, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Sleep Medicine|July 25, 2017
Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active referenceJed Black, Giora Pillar, Jan Hedner, et al.
JAMA Network Open|December 28, 2019
Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical TrialRussell Rosenberg, Patricia Murphy, Gary Zammit, et al.
CNS Drugs|July 21, 2023
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and ZolpidemTobias Di Marco, Thomas E Scammell, Michael Meinel, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|July 20, 2021
Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsyRussell Rosenberg, Michael J Thorpy, Yves Dauvilliers, et al.
Journal of Clinical Sleep Medicine : JCSM : Official Publication of the American Academy of Sleep Medicine|October 26, 2017
Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled StudyPatricia Murphy, Margaret Moline, David Mayleben, et al.
Sleep|June 26, 2020
Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2Mikko Kärppä, Jane Yardley, Kate Pinner, et al.
Behavioral Sleep Medicine|June 13, 2024
Integration of Sensor-Based and Self-Reported Metrics in a Sleep Diary: A Pilot ExplorationSarah Conklin, Jessica R Dietch, Golshan Kargosha, et al.
The Lancet. Neurology|January 22, 2022
Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trialsEmmanuel Mignot, David Mayleben, Ingo Fietze, et al.
Journal of Clinical Pharmacology|April 24, 2015
Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjectsNaoto Uemura, Jacqueline McCrea, Hong Sun, et al.
Journal of Sleep Research|June 10, 2024
Hyperarousal features in the sleep architecture of individuals with and without insomniaTobias Di Marco, Thomas E Scammell, Kolia Sadeghi, et al.
Pageof 6